.START 

Amgen Inc. said its second-quarter earnings increased more than tenfold to $3.9 million, or 22 cents a share, due to increased sales of the company's new antianemia drug for kidney patients. 

The Thousand Oaks, Calif.-based biotechnology company reported a 97% increase in revenue to $42.5 million for the quarter ended Sept. 30.
In the year-ago period, Amgen reported net income of $320,000, or two cents a share, on revenue of $21.5 million. 

For the six months, the company reported a more than sixfold increase in earnings to $4.7 million, or 26 cents a share, from $625,000, or four cents a share a year ago.
Revenue rose 77% to $72.6 million, from last year's $41 million. 

